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Abstract
Papillary neoplasm of breast comprises of seven separate heterogeneous entities 
ranging from benign, atypical and malignancy including non-invasive and invasive 
carcinoma. Papillary carcinoma (PC) is seen more commonly in older postmeno-
pausal women with favorable prognosis. PC breast typically presents with bloody 
nipple discharge and an abnormal mass with radiologic features of intraductal mass. 
Encapsulated PC and solid PC is to be treated as in situ carcinoma, but distinction 
of invasive PC from non invasive carcinoma is critical both at microscopic and 
molecular level. So, surgical excision should be the choice of definitive diagnostic 
technique in papillary neoplasm instead of core needle biopsy. Furthermore, treat-
ment guidelines for invasive PC also have been framed, but incidence of recurrence 
and death attributable to various subtypes of carcinoma remained same. So, this is 
important topic to be addressed to understand the need for further management 
and outcome of the disease.
Keywords: papilloma, invasive carcinoma, intraductal, carcinoma in situ,  
solid papillary carcinoma
1. Introduction
Papillary neoplasm of the breast is a broad range of heterogeneous group of 
lesions that are characterized by presence of papillae supported by fibrovascular 
cores lined by epithelial cells with or without myoepithelial cell layer. These neo-
plasms may be benign, atypical or malignant and are difficult to diagnose. The main 
diagnostic concern is differentiating benign and malignant lesions, which can be 
challenging both on imaging as well as on histopathological examination [1].
2. Definition of papillary neoplasm breast
World health organization (WHO) in 2021 classified breast intraductal papillary 
neoplasm as intraductal papillomas (intraductal papilloma with atypical hyper-
plasia, intraductal papilloma with ductual carcinoma in situ (DCIS), intraductal 
papilloma with lobular carcinoma in situ), intraductal papillary carcinoma (solid 




3.1 Age and sex
The benign conditions are commonly seen in between 30 and 50 years of age 
and PC commonly affects postmenopausal age group. Papillary neoplasms have sex 
predilection for females though intracystic papillary carcinoma (IPC) is rarely seen 
in males too. The clinical presentation in males and females is similar except for a 
higher median age in males [3, 4].
3.2 Incidence
Papillary neoplasms are less commonly seen and account for less than 3% of 
breast tumors and PC of the breast accounts for 0.5–1% of breast cancer [5]. The 
frequency of lymph node involvement in invasive papillary carcinoma, its local 
recurrence and distant recurrence may be 0–11%, 3–70% and 0–4%, respectively. 
Solid papillary carcinoma (SPC) constitutes only 1% of all the breast carcinomas, 
presenting as localized mass in approximately 90% of the cases, lymph node 
metastases in 8%, and distant metastases in less than 0.8% only. Intracystic papil-
lary carcinoma also has localized involvement in approximately 89.6% of the cases 
with 0.4% distant metastases [6, 7].
4. Pathophysiology
Many researchers have analyzed the risk factors for malignant transformation 
in benign papilloma of breast, however the results remain inconsistent. Some 
investigators considered same attributable factors for carcinoma arising in papillary 
neoplasm as that of other carcinomas. The contributing predisposing risk factors 
are age, family history, genetic predilection, diet and weight gain, alcoholism, and 
endocrine factors [8, 9].
5. Clinical features
Papillary neoplasms may be central and peripheral in location and solitary or 
multiple in number. And most papillomas are centrally located with a wide age 
distribution and originate in the large ducts, and are typically solitary. The most 
common clinical presentation is serous or serosanguineous nipple discharge. 
The benign solitary papilloma has 1.5 to 2.0 times high risk of breast carcinoma 
whereas four times increased risk of malignant transformation is noted in atypi-
cal papillomas. The peripheral papillomas arise in the terminal duct lobular units 
and are often discovered incidentally on imaging studies and risk of carcinoma 
is even higher than solitary papilloma. And very rarely, benign papillomas of 
breast presenting with local or distant metastases have been reported [10–18]. 
However, behavior and management of papillary carcinoma whether in situ or 
invasive remain a matter of debate. The lymph node involvement, local recur-
rence and distant recurrence may be seen. Solid papillary carcinoma are localized 
lesions and may involve lymph node however distant metastasis is rare [6, 7]. 
Common clinical features include nipple discharge and palpable masses in some 
cases, however papillary lesions may be diagnosed in asymptomatic women or on 
screening [19].
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6. Diagnosis
Treatment of benign papillary neoplasms require careful evaluation as the 
presence of papillary architecture is known to be associated with a higher risk of 
carcinoma breast [20]. The precise diagnosis of papillary neoplasm of the breast 
is difficult on cytomorphological charaterstics alone. A benign diagnosis on fine 
needle aspiration or core needle biopsy may not completely exclude malignancy 
especially if it manifests as focal carcinoma in-situ or abruption of the myoepithe-
lial layer. Microcalcification is an important factor in the management of breast 
intraductal papillomas diagnosed on core biopsy [21–24]. The benign papillary 
lesions can be diagnosed with sonographically guided 14-gauge core needle biopsy. 
The sensitivity for detecting papillary lesions is greater by ultrasound than mam-
mography. The USG findings of papillary neoplasm are found to be correlated with 
pathologic findings [13, 25]. Recently, automated breast ultrasound scanners have 
been developed, and the ultrasound volume data set of the whole breast can be 
acquired in a standard manner [26]. MRI features including a mass size exceeding 
10 mm may indicate a papilloma with high-risk or malignant lesions [27].
However, histopathological examination is the gold standard tool for the 
diagnosis. Nevertheless, the morphology is more important than the immunos-
taining pattern, and diagnosis of neoplastic proliferation should not be made on 
the immunostaining pattern alone. For intraductal papillary neoplasm CK5/6 
is good marker to differentiate between intraductal hyperplasia (CK5/6 posi-
tive) and intraductal proliferation resembling DCIS or ADH (CK5/6 negative). 
Immunohistochemical examination with CK5/6 and a panel of two myoepithelial 
markers (p63, SMA, CD10, calponin) acts as useful tool in assessing papillary 
neoplasms of the breast [28, 29].
7. Treatment and prognosis
The treatment of benign and atypical papilloma is being evolved. The surgical 
excision of all papillary lesions is recommended for definitive diagnosis and stan-
dard management for malignant papillary lesions [24, 30]. Li X et al. suggested the 
vacuum assisted excision is applicable for complete excision of small papillomas, 
even papillomas with atypical hyperplasia [31]. Bianchi et al. also emphasized that, in 
addition to surgery, vacuum assisted excision of beingn intraductal papilloma may be 
done [32]. However, some authors have recommended that benign papillary lesions 
diagnosed by core needle biopsy (CNB) might not require immediate excision, but 
may be safely managed with imaging follow-up for at least 5 years rather than with 
surgical excision [33, 34]. Accurate results and coordination between a trained 
radiologist and pathology are of utmost importance in the decision making between 
follow-up or surgery [35]. However, Fatima K et al. have observed no reliable clinical 
or imaging features that can pre-surgically predict atypical upgradation or malignant 
potential [30]. Tokiniwa H and fellows detected surgical excision advantageous for 
papillary lesions especially for the lesions located far from the nipple [36]. The atypi-
cal papillary lesions should be excised surgically (Figure 1) [37].
Intraductal carcinomas like encapsulated papillary carcinoma (EPC) with 
presence of myoepithelial cells at the periphery should be treated as DCIS and with 
lack of myoepithelial cells may behave in an indolent invasive pattern with reported 
lymphnode metastasis and lymphovascular invasion. The present harmony is to 
manage EPC as in situ disease, though recurrence may be seen associated with 
aggressive behavior (Figure 2).
Global Women’s Health
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Due to lack of evidence of behavior and criterion of diagnosis, SPC is difficult to 
categorize as benign or malignant and current consensus is to consider it as an in-
situ disease. Consensus is to treat these types of neoplasms for local control without 
axillary node sampling or systemic therapy. Inspite of very low risk of metastatic 
potential, evidence does not support use of conventional forms of adjuvant systemic 
therapy. IPC is known to have benign behavior with 100% disease-specific survival 
rate so to be treated with similar way to other types of carcinoma breast except in 
cases with moderate nuclear atypia [7, 38].
8. Conclusion
Papillary neoplasm is difficult to detect and diagnose, if diagnosed, surgical 
excision is the treatment of choice. Encysted and solid papillary carcinoma should 
Figure 1. 
Surgically excised specimen of papillary neoplasm.
Figure 2. 
Surgically excised specimen of EPC.
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be treated as DCIS, irrespective of nuclear grading. Amongst imaging studies ultra-
soography is better than mammography. In difficult cases immunohistochemical 
markers (CK 5/6 and minimum two myeloepithelial markers provide the support. 
Invasive papillary carcinoma may be treated as per guidelines of invasive carcinoma 
breast and shows good prognosis.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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